Addex Therapeutics Ltd. (ADXN)
|Net Income (ttm)||-12.72M|
|Trading Day||May 7|
|Day's Range||9.58 - 9.97|
|52-Week Range||7.00 - 37.52|
KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd. a provider of drug discovery services empowered with the world's largest collections of building blocks, fragments and screening compounds announced today th...
Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone...
Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is...
Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and col... [Read more...]
Pharmaceutical Preparation Manufacturing
|Stock Exchange |
|Ticker Symbol |
In 2020, ADXN's revenue was 3.61 million, an increase of 30.77% compared to the previous year's 2.76 million. Losses were -12.86 million, -13.00% less than in 2019.